Literature DB >> 11064345

Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53.

D Chendil1, R Oakes, R A Alcock, N Patel, C Mayhew, M Mohiuddin, V S Gallicchio, M M Ahmed.   

Abstract

BACKGROUND: The current study was undertaken to investigate the influence of wild-type or mutant p53 status on the radiosensitizing effect of paclitaxel in colorectal tumor cell lines.
METHODS: HCT-116 (contains wild-type p53) and HT-29 (contains mutant p53) established from moderately differentiated colorectal carcinomas were used in this study. Colony-forming assay was performed after exposure to either different radiation doses (0.5-6 gray [Gy]) or paclitaxel (1-10 nM) or in combination. Induction of p53 and p21(waf1/cip1) by these treatments were determined by immunocytochemistry and Western blot analysis.
RESULTS: Radiation caused an increase in nuclear p53 and p21(waf1/cip1) proteins in HCT-116 cells, indicating that p53 functionally induced p21(waf1/cip1). However, induction of nuclear p53 and p21(waf1/cip1) protein was not evident in HT-29 cells, suggesting that p53 was not functional in these cells. Survival data showed that the HCT-116 cells (survival fraction of exponentially growing cells that were irradiated at the clinically relevant dose of 2 Gy [SF(2)] = 0.383; dose required to reduce the fraction of cells to 37% [D(0)] = 223 centigray [cGy]) were significantly sensitive to ionizing radiation (P < 0.008) when compared with the HT-29 cells (SF(2) = 0.614; D(0) = 351 cGy). Paclitaxel caused a higher degree of clonogenic inhibition in HCT-116 (D(0) = 0.7 nM) than HT-29 (D(0) = 1.11 nM) cells (P < 0.06). When paclitaxel and radiation were combined, an enhanced radiosensitizing effect (P < 0.05) was observed in HCT-116 cells (SF(2) = 0.138; D(0) = 103 cGy), whereas in HT-29 cells no significant radiosensitization of paclitaxel was observed (SF(2) = 0.608; D(0) = 306 cGy). However, pretreatment with paclitaxel followed by multifractionated low dose radiation (0.5- or 1-Gy fractions for a total dose of 2 Gy) significantly enhanced the radiosensitizing effect in both HCT-116 and HT-29 cells.
CONCLUSIONS: The results of the current study suggested that multifractionated radiation given at very low doses after exposure of cells to paclitaxel conferred a potent radiation sensitizing effect irrespective of p53 status. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11064345     DOI: 10.1002/1097-0142(20001101)89:9<1893::aid-cncr4>3.3.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  Tumor cell migration is not influenced by p21 in colon carcinoma cell lines after irradiation with X-ray or (12)C heavy ions.

Authors:  Kristina Goetze; Michael Scholz; Gisela Taucher-Scholz; Wolfgang Mueller-Klieser
Journal:  Radiat Environ Biophys       Date:  2010-06-10       Impact factor: 1.925

2.  Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.

Authors:  Charles A Kunos; Michael W Sill; Thomas E Buekers; Joan L Walker; Jeanne M Schilder; S Diane Yamada; Steven E Waggoner; Mohammed Mohiuddin; Paula M Fracasso
Journal:  Gynecol Oncol       Date:  2011-02       Impact factor: 5.482

Review 3.  Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy.

Authors:  Anish Prasanna; Mansoor M Ahmed; Mohammed Mohiuddin; C Norman Coleman
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

4.  Adenovirus-mediated p53 gene transfer sensitizes hepatocellular carcinoma cells to heavy-ion radiation.

Authors:  Bing Liu; Hong Zhang; Guangming Zhou; Yi Xie; Jifang Hao; Rong Qiu; Xin Duan; Qingming Zhou
Journal:  J Gastroenterol       Date:  2007-03-12       Impact factor: 7.527

5.  p16INK4a Status and Response to Induction Low-Dose Fractionated Radiation in Advanced Head and Neck Cancer.

Authors:  Natalie L Silver; Susanne M Arnold; John F Gleason; Mahesh Kudrimoti; Yolanda Brill; Emily V Dressler; Joseph Valentino
Journal:  Ann Otol Rhinol Laryngol       Date:  2015-03-25       Impact factor: 1.547

6.  Comparison of two radiation techniques for the breast boost in patients undergoing neoadjuvant treatment for breast cancer.

Authors:  Maria C De Santis; Luigia Nardone; Barbara Diletto; Roberta Canna; Michela Dispinzieri; Lorenza Marino; Laura Lozza; Vincenzo Valentini
Journal:  Br J Radiol       Date:  2016-07-25       Impact factor: 3.039

7.  Involvement of miR-155/FOXO3a and miR-222/PTEN in acquired radioresistance of colorectal cancer cell line.

Authors:  Hamed Manoochehri Khoshinani; Saeid Afshar; Abdolazim Sedighi Pashaki; Ali Mahdavinezhad; Safora Nikzad; Rezvan Najafi; Razieh Amini; Mohammad Hadi Gholami; Alireza Khoshghadam; Massoud Saidijam
Journal:  Jpn J Radiol       Date:  2017-09-06       Impact factor: 2.374

8.  MRI evaluation of neoadjuvant low-dose fractionated radiotherapy with concurrent chemotherapy in patients with locally advanced breast cancer.

Authors:  E Bufi; P Belli; M Costantini; P Rinaldi; M Di Matteo; A Bonatesta; M C De Santis; L Nardone; D Terribile; A Mulé; L Bonomo
Journal:  Br J Radiol       Date:  2012-07-04       Impact factor: 3.039

9.  Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.

Authors:  Mario Balducci; Silvia Chiesa; Barbara Diletto; Giuseppe Roberto D'Agostino; Annunziato Mangiola; Stefania Manfrida; Giovanna Mantini; Alessio Albanese; Alba Fiorentino; Vincenzo Frascino; Berardino De Bari; Francesco Micciche'; Fiorenza De Rose; Alessio Giuseppe Morganti; Carmelo Anile; Vincenzo Valentini
Journal:  Neuro Oncol       Date:  2011-10-12       Impact factor: 12.300

10.  Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma: final report of a pilot study.

Authors:  M Balducci; B Diletto; S Chiesa; G R D'Agostino; M A Gambacorta; M Ferro; C Colosimo; G Maira; C Anile; V Valentini
Journal:  Strahlenther Onkol       Date:  2014-01-17       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.